Halozyme Therapeutics, Inc. Gross Profit 2009–2025
Halozyme Therapeutics, Inc. reported $1.17B of gross profit for fiscal 2025. That was 36.4% higher than fiscal 2024. Compared with fiscal 2020, the change was +420.8%.
| Fiscal year | Gross Profit | Gross margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $1.17B | 83.6% | +36.4% |
| FY 2024 | $855.91M | 84.3% | +34.4% |
| FY 2023 | $636.89M | 76.8% | +22.3% |
| FY 2022 | $520.81M | 78.9% | +43.9% |
| FY 2021 | $361.90M | 81.6% | +61.4% |
| FY 2020 | $224.23M | 83.8% | +49.0% |
| FY 2019 | $150.45M | 76.8% | +6.2% |
| FY 2018 | $141.73M | 93.3% | -50.4% |
| FY 2017 | $285.46M | 90.2% | +151.5% |
| FY 2016 | $113.48M | 77.4% | +7.3% |
| FY 2015 | $105.81M | 78.3% | +101.2% |
| FY 2014 | $52.60M | 69.8% | +8.3% |
| FY 2013 | $48.55M | 88.6% | +17.8% |
| FY 2012 | $41.23M | 97.4% | -26.1% |
| FY 2011 | $55.83M | 99.5% | +341.7% |
| FY 2010 | $12.64M | 92.8% | -5.4% |
| FY 2009 | $13.36M | 97.7% | — |
Source: Halozyme Therapeutics, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HALO 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Halozyme Therapeutics, Inc. reported $1.17B of gross profit for fiscal 2025. That was 36.4% higher than fiscal 2024. Compared with fiscal 2020, the change was +420.8%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Halozyme Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHalozyme Therapeutics, Inc. — frequently asked questions
What is Halozyme Therapeutics, Inc.'s gross profit?
Halozyme Therapeutics, Inc. (HALO) reported gross profit of $1.17B for fiscal year 2025, per its SEC filings.
How has Halozyme Therapeutics, Inc.'s gross profit changed over time?
Between fiscal 2009 and 2025, HALO's gross profit grew at roughly 32.2% per year (compound annual rate), from $13.36M to $1.17B.
Where does this data come from?
Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.